Search Results 31-40 of 13323 for monoclonal antibody

  1. Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients with Refractory or Relapsed Neuroblastoma - Mayo Clinic

    Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find ...

  2. Hodgkin Clinical Trials - Mayo Clinic Research

    Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a combining ...

  3. Phase 1/2 Dose Escalation And Efficacy Study Of Anti-CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies - Mayo Clinic

    Phase 1/2 Dose Escalation And Efficacy Study Of Anti-CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies · More about research at ...

  4. Lymphoma Clinical Trials - Mayo Clinic Research

    Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or ...

  5. A Phase 1 Dose Escalation And Cohort Expansion Study Of TSR-042, An Anti-PD-1 Monoclonal Antibody, In Patients With Advanced Solid Tumors - Mayo Clinic

    A Phase 1 Dose Escalation And Cohort Expansion Study Of TSR-042, An Anti-PD-1 Monoclonal Antibody, In Patients With Advanced Solid Tumors · Overview.

  6. Immunization and antiserum collection - Antibody Hybridoma Core - Mayo Clinic Research

    The Antibody Hybridoma Core at Mayo Clinic produces monoclonal antibodies using immunized mice housed in a pathogen-free colony.

  7. A Study to Evaluate TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies to treat participants who have relapsed or refractory multiple myeloma.

  8. Hematology - Clinical trials - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer ...

  9. Mayo Clinic secures ARPA-H award to build a living pharmacy within the body for inflammatory disease

    Monoclonal antibodies are engineered to target specific proteins involved in the inflammatory process, helping to reduce inflammation and manage symptoms of IBD ...

  10. Non-Hodgkin's Lymphoma Clinical Trials - Mayo Clinic Research

    Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant ...